Akari Therapeutics appoints Vatnak Vat-Ho chief business officer

By Public Technologies
  • Akari Therapeutics named Vatnak Vat-Ho chief business officer to lead corporate strategy, partnering, licensing, investor engagement.
  • Vat-Ho brings 20+ years in oncology business development, biopharma strategy, equity research, healthcare investing; worked on deals totaling $25 billion.
  • Most recently served as chief business officer at Ryvu Therapeutics, where he closed an ADC payload collaboration with Exelixis.
  • At Ryvu, he also originated a multi-target immuno-oncology research collaboration with BioNTech.
  • Appointment comes as Akari advances TROP2-targeted ADC AKTX-101 toward the clinic, alongside its PH1 payload platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130901PRIMZONEFULLFEED9844277) on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.